These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30873379)

  • 21. 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent.
    Ghafouri-Fard S; Abak A; Tondro Anamag F; Shoorei H; Fattahi F; Javadinia SA; Basiri A; Taheri M
    Front Oncol; 2021; 11():658636. PubMed ID: 33954114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
    Li Santi A; Napolitano F; Montuori N; Ragno P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of uPA and uPAR expression in patients with cervical cancer undergoing radiotherapy.
    Nantajit D; Chailapakul P; Bawornpatarapakorn S; Chamchod S; Laebua K
    Oncol Lett; 2021 May; 21(5):423. PubMed ID: 33850564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance.
    Cetin R; Quandt E; Kaulich M
    Cells; 2021 Jan; 10(2):. PubMed ID: 33525637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.
    Azangou-Khyavy M; Ghasemi M; Khanali J; Boroomand-Saboor M; Jamalkhah M; Soleimani M; Kiani J
    Front Immunol; 2020; 11():2062. PubMed ID: 33117331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial.
    Fosbøl MØ; Kurbegovic S; Johannesen HH; Røder MA; Hansen AE; Mortensen J; Loft A; Petersen PM; Madsen J; Brasso K; Kjaer A
    J Nucl Med; 2021 Mar; 62(3):354-359. PubMed ID: 32764119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.
    Mahmood N; Arakelian A; Khan HA; Tanvir I; Mazar AP; Rabbani SA
    Bone Res; 2020; 8():18. PubMed ID: 32337090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survivin Promotes Piperlongumine Resistance in Ovarian Cancer.
    Nan XW; Gong LH; Chen X; Zhou HH; Ye PP; Yang Y; Xing ZH; Wei MN; Li Y; Wang ST; Liu K; Shi Z; Yan XJ
    Front Oncol; 2019; 9():1345. PubMed ID: 31850227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translatable gene therapy for lung cancer using Crispr CAS9-an exploratory review.
    Nair J; Nair A; Veerappan S; Sen D
    Cancer Gene Ther; 2020 Apr; 27(3-4):116-124. PubMed ID: 31222183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
    Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
    Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
    Chavakis T; Kanse SM; May AE; Preissner KT
    Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance.
    Wang K; Xing ZH; Jiang QW; Yang Y; Huang JR; Yuan ML; Wei MN; Li Y; Wang ST; Liu K; Shi Z
    Front Oncol; 2019; 9():80. PubMed ID: 30873379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.
    Yang Y; Qiu JG; Li Y; Di JM; Zhang WJ; Jiang QW; Zheng DW; Chen Y; Wei MN; Huang JR; Wang K; Shi Z
    Am J Transl Res; 2016; 8(9):3986-3994. PubMed ID: 27725879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.
    Biagioni A; Chillà A; Del Rosso M; Fibbi G; Scavone F; Andreucci E; Peppicelli S; Bianchini F; Calorini L; Li Santi A; Ragno P; Margheri F; Laurenzana A
    Front Oncol; 2021; 11():663225. PubMed ID: 34055629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
    Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
    BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.